MedTrace Logo

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2026-01-07

No results posted yet for this study

Summary

This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.

Conditions

Interventions

BIOLOGICAL

Non-interventional hormone therapy

Therapy given outside of this study as part of standard of care

PROCEDURE

Prostate Biopsy

Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion

PROCEDURE

Radiotherapy (RT)

Radiation therapy given outside of this study

PROCEDURE

Multi-parametric magnetic resonance imaging (mpMRI)

Imaging scan

DRUG

hyperpolarized pyruvate +/-urea (13C/15N)

Given IV

RADIATION

Non-investigational External beam radiotherapy (EBRT)

External beam radiotherapy given outside of this study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Robert Bok, MD, PhD

    lead OTHER

Principal Investigators

  • Robert Bok, MD, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-24
Primary Completion
2028-12-31
Completion
2032-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06391034 on ClinicalTrials.gov